Literature DB >> 20425088

Orthopedic uses of teriparatide.

Susan V Bukata1, J Edward Puzas.   

Abstract

Teriparatide is a drug currently approved for treating patients with osteoporosis who are at high risk for future fracture. In the treatment of osteoporosis, teriparatide works as an anabolic agent stimulating bone formation throughout the skeleton by principally enhancing osteoblast-derived bone formation relative to osteoclast-derived bone resorption. The net effect is increased bone mass. For patients with a fracture, a similar process of increased bone formation is required transiently at the fracture site for repair. Teriparatide has been investigated in animal models and in patients as a potential agent to enhance fracture repair. In addition, evidence that teriparatide enhances chondrogenesis has generated interest in using the agent for articular cartilage repair. Research is currently underway to understand the effects teriparatide may have on mesenchymal stem cells, and on other effects that have been reported anecdotally in patients using the drug for osteoporosis care, including the healing of fracture nonunions and a decreased incidence of back pain. We review the current animal and human reports available on the uses of teriparatide in musculoskeletal diseases beyond osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425088     DOI: 10.1007/s11914-010-0006-3

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  20 in total

1.  Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing.

Authors:  Tetsuro Nakazawa; Arata Nakajima; Koji Shiomi; Hideshige Moriya; Thomas A Einhorn; Masashi Yamazaki
Journal:  Bone       Date:  2005-09-06       Impact factor: 4.398

2.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

3.  Role of bone scintigraphy in the evaluation and treatment of nonunited fractures: concise communication.

Authors:  A Desai; A Alavi; M Dalinka; C Brighton; J Esterhai
Journal:  J Nucl Med       Date:  1980-10       Impact factor: 10.057

4.  Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34).

Authors:  Yaser M Alkhiary; Louis C Gerstenfeld; Elizabeth Krall; Michael Westmore; Masahiko Sato; Bruce H Mitlak; Thomas A Einhorn
Journal:  J Bone Joint Surg Am       Date:  2005-04       Impact factor: 5.284

5.  Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.

Authors:  D W Dempster; F Cosman; E S Kurland; H Zhou; J Nieves; L Woelfert; E Shane; K Plavetić; R Müller; J Bilezikian; R Lindsay
Journal:  J Bone Miner Res       Date:  2001-10       Impact factor: 6.741

6.  Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone.

Authors:  J M Hock; I Gera
Journal:  J Bone Miner Res       Date:  1992-01       Impact factor: 6.741

7.  Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys.

Authors:  Takeshi Manabe; Satoshi Mori; Tasuku Mashiba; Yoshio Kaji; Ken Iwata; Satoshi Komatsubara; Azusa Seki; Yong-Xin Sun; Tetsuji Yamamoto
Journal:  Bone       Date:  2007-02-02       Impact factor: 4.398

8.  Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures.

Authors:  Sanjeev Kakar; Thomas A Einhorn; Siddharth Vora; Lincoln J Miara; Gregory Hon; Nathan A Wigner; Daniel Toben; Kimberly A Jacobsen; Maisa O Al-Sebaei; Michael Song; Philip C Trackman; Elise F Morgan; Louis C Gerstenfeld; George L Barnes
Journal:  J Bone Miner Res       Date:  2007-12       Impact factor: 6.741

9.  Parathyroid hormone 1-34 inhibits terminal differentiation of human articular chondrocytes and osteoarthritis progression in rats.

Authors:  Je-Ken Chang; Ling-Hwa Chang; Shao-Hung Hung; Shun-Cheng Wu; Hsin-Yi Lee; Yi-Shan Lin; Chung-Hwan Chen; Yin-Chih Fu; Gwo-Jaw Wang; Mei-Ling Ho
Journal:  Arthritis Rheum       Date:  2009-10

10.  Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay.

Authors:  G N Kent; N Loveridge; J Reeve; J M Zanelli
Journal:  Clin Sci (Lond)       Date:  1985-02       Impact factor: 6.124

View more
  23 in total

1.  Delayed short-course treatment with teriparatide (PTH(1-34)) improves femoral allograft healing by enhancing intramembranous bone formation at the graft-host junction.

Authors:  Masahiko Takahata; Edward M Schwarz; Tony Chen; Regis J O'Keefe; Hani A Awad
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

Review 2.  A literature review and case series of accelerating fracture healing in postmenopausal osteoporotic working women.

Authors:  Srinivas K Rao; Anitha P Rao
Journal:  J Orthop       Date:  2014-07-18

3.  Osteoporotic fracture and parathyroid hormone.

Authors:  Nabanita S Datta
Journal:  World J Orthop       Date:  2011-08-18

4.  Evaluation of the effect of teriparatide therapy on mandibular fracture healing in rats with medication-related osteonecrosis of the jaw.

Authors:  Mohammad Zandi; Arash Dehghan; Payam Amini; Shideh Doulati; Leila Rezaeian
Journal:  Clin Oral Investig       Date:  2019-02-04       Impact factor: 3.573

5.  An unexpected healing of an established non union of the radial neck through teriparatide: A case report and review of literature.

Authors:  Bhavuk Garg; Sahil Batra; Vivek Dixit
Journal:  J Clin Orthop Trauma       Date:  2017-10-27

Review 6.  Choosing a treatment for patients at the time a fracture is presented.

Authors:  S Bobo Tanner
Journal:  Curr Osteoporos Rep       Date:  2011-09       Impact factor: 5.096

7.  PTH-enhanced structural allograft healing is associated with decreased angiopoietin-2-mediated arteriogenesis, mast cell accumulation, and fibrosis.

Authors:  Robinder S Dhillon; Chao Xie; Wakenda Tyler; Laura M Calvi; Hani A Awad; Michael J Zuscik; Regis J O'Keefe; Edward M Schwarz
Journal:  J Bone Miner Res       Date:  2013-03       Impact factor: 6.741

Review 8.  Endogenous tissue engineering: PTH therapy for skeletal repair.

Authors:  Masahiko Takahata; Hani A Awad; Regis J O'Keefe; Susan V Bukata; Edward M Schwarz
Journal:  Cell Tissue Res       Date:  2011-05-31       Impact factor: 5.249

Review 9.  Effect of osteoporosis medications on fracture healing.

Authors:  V Hegde; J E Jo; P Andreopoulou; J M Lane
Journal:  Osteoporos Int       Date:  2015-09-29       Impact factor: 4.507

10.  A Guide to Improving the Care of Patients with Fragility Fractures, Edition 2.

Authors:  Simon C Mears; Stephen L Kates
Journal:  Geriatr Orthop Surg Rehabil       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.